CVasThera

Executive Summary

CVasThera is a French biopharmaceutical company founded in 2016 that specializes in acquiring, optimizing, and advancing early-stage small molecule therapeutics for cardiovascular and inflammatory diseases. Operating at the pre-clinical stage, the company acts as a 'booster' by leveraging deep industry expertise to accelerate promising molecules to clinical proof-of-concept. Its pipeline targets indications such as atrial fibrillation, myocardial infarction, and Crohn's disease, reflecting a strategic focus on reimagining innovative compounds with the potential to improve patient outcomes. While CVasThera's asset-centric model reduces early-stage risk through selective acquisition, its progress hinges on successful optimization and timely advancement of lead candidates into the clinic.

Upcoming Catalysts (preview)

• Q1 2027Lead candidate selection for IND-enabling studies50% success
• Q4 2026Preclinical data readout in cardiovascular indication40% success
• H2 2026Partnership or licensing deal for one of its programs35% success